The primary objective of the study is to verify that the manufacturing equivalence of Sci-B-Vac™ is consistent and to compare the immunogenicity and safety of a three-dose regimen of Sci-B-Vac™ to a three-dose regimen of Engerix-B® in adults.
https://clinicaltrials.gov/ct2/show/NCT03408730?term=Sci-B-Vac-002&rank=1